Electroacupuncture reduced cellular hallmarks of Parkinson’s disease, including alpha-synuclein accumulation and nerve cell degeneration, in a mouse model of the disease. That’s according to the findings from a study that also found the treatment, a type of acupuncture where small needles inserted at specific points in the body are…
Ncardia has launched a panel of ready-to-use cell-based assays to simplify the screening and selection of treatment candidates for neurodegenerative diseases, including Parkinson’s disease. The assays are based on human-derived induced pluripotent stem cells (iPSCs), a type of stem cell that can generate nearly all types of cells.
Navamedic is partnering with Alex Therapeutics to offer a new companion app to people with Parkinson’s disease who are treated with Flexilev, the former’s water-soluble minitablet formulation of levodopa and carbidopa. The app, which will be developed by Alex Therapeutics, will provide medication management tools tailored to…
Scientists have discovered how to therapeutically target a class of molecular switches called GTPases that are involved in Parkinson’s disease and other conditions but have long been considered undruggable. The findings of this work, led by researchers at the University of California, San Francisco (UCSF), “create a long-awaited opportunity…
Rune Labs has launched StrivePD-AI, a new feature in its StrivePD app that uses generative artificial intelligence (GenAI) to create monthly clinical reports based on a continuous stream of observations that show how Parkinson’s disease is progressing in the app’s users over time. The company is cleared…
The American Parkinson Disease Association (APDA) has awarded a total of $2.6 million for the 2024-2025 funding year, to support a range of research projects that aim to advance understanding of Parkinson’s disease. The nationwide grassroots network increased its funding package by more than 30% over last year,…
The U.S. Food and Drug Administration (FDA) has cleared Turing Medical’s automated brain mapping technology designed to help doctors develop personalized plans for deep brain stimulation (DBS) and other neuromodulation therapies in people with neurological conditions such as Parkinson’s disease. Called Bullsai Identify, the platform uses artificial intelligence…
People with a history of damage to the lining of the upper gastrointestinal (GI) tract, called the gastrointestinal mucosa, had an elevated risk of developing Parkinson’s disease in a recent U.S. study. “We found that a history of upper GI mucosal damage was associated with a 76% greater risk…
The first patient with early Parkinson’s disease has been dosed in Ventyx Biosciences‘ Phase 2a clinical trial of Parkinson’s therapy VTX3232, an oral medication designed to reduce inflammation by blocking the activity of the NLRP3 protein. The trial is still recruiting patients at its single site in…
The U.S. Food and Drug Administration (FDA) is encouraging scientists and drug developers to use an alpha-synuclein seed amplification assay (synSAA) to improve the development and efficiency of clinical trials seeking to delay or prevent the development of Parkinson’s and other neurodegenerative diseases that share toxic clumps of that protein…
Get regular updates to your inbox.